FDA Approves Adamas Pharmaceuticals' Alzheimer's Drug; Endo Pharma and BioDelivery Announce NDA Submission for Buprenorphine HCl Buccal Film Print E-mail
By David Fowler   
Wednesday, 24 December 2014 13:26
Below is a look at some of the headlines for companies that made news in the healthcare sector on December 24, 2014.

The FDA on Wednesday approved a New Drug Application for Adamas Pharmaceuticals Inc's (NASDAQ: ADMS) Namzaric for the treatment of moderate to severe dementia of the Alzheimer's type.

Namzaric will be available in two dosage strengths, 28/10 mg and 14/10 mg for patients with severe renal impairment.

"Namzaric combines, in one capsule, two complementary therapeutic agents which are often co-prescribed as approximately 70% of Namenda XR patients are also on AChEI therapy. Both Namenda XR and donepezil have proven efficacy and safety, for the treatment of moderate to severe Alzheimer's disease. Additionally, data has shown that combination therapy with Namenda XR and an AChEI demonstrated greater improvement in cognition and global function verses an AChEI alone," said David Nicholson, Actavis Senior Vice President, Global Brands R&D in a statement.

Adamas Pharmaceuticals jointly created the drug with Forest Laboratories, a recent acquisition of Actavis. Actavis will have exclusive U.S. commercialization rights while Adamas Pharmaceuticals will retain exclusive commercialization rights outside of the United States.

Namzaric is expected to be launched in the United States during the second quarter of 2015.

Shares of Adamas Pharmaceuticals were trading higher by nearly 21 percent Wednesday morning.





===========================


 


Endo Pharmaceuticals Inc., a subsidiary of Endo International plc (NASDAQ: ENDP) (NYSE: ENL), and BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that they have submitted a New Drug Application (NDA) for Buprenorphine HCl Buccal Film to the U.S. Food and Drug Administration (FDA). Buprenorphine HCl Buccal Film is under development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and
for which alternative treatment options are inadequate.

The drug uses BDSI's patented BioErodible MucoAdhesive (BEMA®) drug delivery technology to efficiently and

Error. Page cannot be displayed. Please contact your service provider for more details. (18)

conveniently deliver buprenorphine across the buccal mucosa (inside lining of the cheek). Buprenorphine, a Schedule III controlled substance, is a partial opioid agonist and
a potent analgesic with a relatively long duration of action. Buprenorphine HCl Buccal Film is being developed and will be commercialized through a worldwide license and development agreement between Endo Pharmaceuticals and BDSI.

"Buprenorphine HCl Buccal Film is Endo's lead development program for our branded pharmaceuticals business representing a potentially important addition to our portfolio of pain medicines," said Rajiv De Silva, President and CEO of Endo. "Today's NDA filing is a significant step forward in our effort to address a need among patients suffering chronic pain. As a leader in the treatment of chronic pain, Endo has extensive experience supporting patients and their physicians, and look forward to continuing that commitment with Buprenorphine HCl Buccal Film."

The two pivotal phase 3 studies for demonstration of safety and efficacy were double-blind randomized, placebo-controlled, enriched-enrollment studies in patients with chronic lower back pain. One study (BUP-307) was conducted in opioid experienced subjects, and the second study (BUP-308) was conducted in subjects naïve to opioid therapy. Both studies met the primary efficacy endpoint of change from baseline to week 12 of mean daily pain intensity score from placebo (BUP- 307; p <.00001 ; BUP – 308; p= .001 ). Buprenorphine HCl Buccal Film was generally well tolerated demonstrating a low incidence of typical opioid like side effects.

"The submission of the NDA for Buprenorphine HCl Buccal Film is a major milestone in BDSI's partnership with Endo Pharmaceuticals," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. "Buprenorphine's role in pain management in the United States has always been hampered by the lack of a convenient and flexible dosage form. We believe our patented BEMA technology will overcome this obstacle and provide physicians with a meaningful product to treat chronic pain. We look forward to continuing our work with Endo, and making this therapy available to patients who need it."


 

Also Wednesday:

 



Allegiant (NASDAQ: ALGT) is helping Make-A-Wish® grant wishes by providing travel for 33 wish kids this holiday season -- kids like 5-year old Jaylen, who was diagnosed with leukemia and wished to go to the Florida theme parks.

Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that the U.S. Food and Drug Administration (FDA) has granted the company's investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) orphan drug designation for the treatment of Retinitis Pigmentosa (RP).

BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX)
today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BCX4161 for the prevention of acute attacks of angioedema in patients with hereditary angioedema (HAE).

BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues  ("BioLife" or the "Company"), today announced that it will hold its 2015 Annual Meeting of Stockholders on May 4, 2015 (the "Annual Meeting").

Cell MedX Corp. (OTCBB: CMXC)
, announces that the Company has appointed Dale Matheson Carr-Hilton LaBonte LLP Chartered Accountants as its new independent auditors replacing Sadler, Gibb & Associates, LLC.

Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded two grants totaling $818,000 to advance the development of an Ebola rapid diagnostic test kit.

MMRGlobal, Inc. (OTCQB: MMRF), through its wholly owned subsidiary, MyMedicalRecords, Inc. (collectively, "MMR"), today announced that the U.S. District Court for the Central District of California issued an order in response to a motion for judgment on the pleadings agreeing that claims 8-12 of U.S. Patent No. 8,301,466 ("the '466 patent") were directed towards an abstract idea and therefore not directed towards patent eligible subject matter.

Monarch America Inc. (OTCQB: CANK) (f/k/a Cannabis Kinetics Corp.) would like to correct the prior news announcement made earlier today regarding the timing of the 3-for-1 forward stock split.

Pharmaceutical Product Development, LLC (PPD) and Shin Nippon Biomedical Laboratories Ltd. (SNBL) (TSE:2395) today announced an agreement to form a joint venture that will provide a full range of clinical development services in Japan, including Phase I-IV clinical trial monitoring, project management, site intelligence and activation, biostatistics, data management, medical writing, pharmacovigilance, regulatory and FSP services.

Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI) announced today that it has filed a Clinical Trial Application (CTA) with the United Kingdom's Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to initiate clinical trials for the continued development of its lead molecule, Anatabine Citrate.

Synageva BioPharma Corp. (NASDAQ: GEVA), a biopharmaceutical company developing therapeutic products for rare disorders, today announced validation by the European Medicines Agency (EMA) of the Marketing Authorization Application (MAA) for sebelipase alfa for LAL Deficiency. 




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BMR:1